PE20020055A1 - Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal - Google Patents
Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasalInfo
- Publication number
- PE20020055A1 PE20020055A1 PE2001000462A PE2001000462A PE20020055A1 PE 20020055 A1 PE20020055 A1 PE 20020055A1 PE 2001000462 A PE2001000462 A PE 2001000462A PE 2001000462 A PE2001000462 A PE 2001000462A PE 20020055 A1 PE20020055 A1 PE 20020055A1
- Authority
- PE
- Peru
- Prior art keywords
- nasal decongestant
- stable liquid
- solid formulations
- formulations including
- sedating antihistamine
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000133 nasal decongestant Substances 0.000 title abstract 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title 1
- 230000001387 anti-histamine Effects 0.000 title 1
- 239000000739 antihistaminic agent Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 abstract 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003088 loratadine Drugs 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 1
- 229960003908 pseudoephedrine Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) DE 0,4mg/ml A 0,7mg/ml DE LORATADINA; b) UN DESCONGESTIONANTE NASAL TAL COMO PSEUDOEFEDRINA, PROPANOLAMINA ; c) UN EXPECTORANTE TAL COMO AMBROXOL Y d) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION CONTIENE ADEMAS UN AGENTE ANTIMICROBIANO, EDULCORANTE, PROPILENGLICOL Y GLICERINA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA ESTABLE EN FORMA LIQUIDA QUE COMPRENDE UNA COMBINACION DE: a) UN EDULCORANTE TAL COMO SORBITOL, SACARIDO DE SODIO; b) UN VEHICULO LIQUIDO Y c) UN SISTEMA BUFFER PARA MANTENER EL pH EN EL RANGO DE 3 A 5. LA COMPOSICION ES ESTABLE A LA CONTAMINACION DE MICROORGANISMOS DURANTE PERIODOS DE 4 MESES A 36 MESES A TEMPERATURA AMBIENTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/2000/005129A MXPA00005129A (es) | 2000-05-24 | Composiciones farmaceuticas antihistaminicas - anticongestivas liquidas estables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020055A1 true PE20020055A1 (es) | 2002-02-12 |
Family
ID=33308448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000462A PE20020055A1 (es) | 2000-05-25 | 2001-05-22 | Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU2001264806A1 (es) |
| BR (1) | BR0111018A (es) |
| CR (1) | CR6804A (es) |
| EC (1) | ECSP024356A (es) |
| PA (1) | PA8517201A1 (es) |
| PE (1) | PE20020055A1 (es) |
| WO (1) | WO2001089527A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635654B1 (en) | 2003-01-09 | 2003-10-21 | Allergan, Inc. | Ophthalmic compositions containing loratadine |
| NZ575838A (en) * | 2005-06-17 | 2010-10-29 | Aft Pharmaceuticals Ltd | Composition comprising loratadine and phenylephrine and its use in a method for treatment of patients with upper respiratory mucosal congestion |
| MX2009000121A (es) * | 2006-06-29 | 2009-01-26 | Schering Corp | Jarabes antihistaminicos, estables en almacenamiento, sin azucar. |
| WO2022159763A1 (en) * | 2021-01-22 | 2022-07-28 | Model Medicines, Inc. | Sars-cov-2 therapeutics |
| CN116898799B (zh) * | 2023-08-30 | 2024-04-30 | 哈尔滨圣泰生物制药有限公司 | 一种地氯雷他定口服制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783465A (en) * | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| EP0719156A1 (en) * | 1993-09-07 | 1996-07-03 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| HUP9904075A3 (en) * | 1996-10-31 | 2002-02-28 | Schering Corp | Composition, for the treatment of asthma,containing loratadine and a decongestant |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| EP1276502A1 (en) * | 2000-04-14 | 2003-01-22 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
-
2001
- 2001-05-22 AU AU2001264806A patent/AU2001264806A1/en not_active Withdrawn
- 2001-05-22 PA PA20018517201A patent/PA8517201A1/es unknown
- 2001-05-22 BR BR0111018-7A patent/BR0111018A/pt not_active Application Discontinuation
- 2001-05-22 PE PE2001000462A patent/PE20020055A1/es not_active Application Discontinuation
- 2001-05-22 WO PCT/US2001/016570 patent/WO2001089527A2/en active Application Filing
-
2002
- 2002-10-31 CR CR6804A patent/CR6804A/es not_active Application Discontinuation
- 2002-11-22 EC EC2002004356A patent/ECSP024356A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001089527A2 (en) | 2001-11-29 |
| BR0111018A (pt) | 2004-02-17 |
| CR6804A (es) | 2008-10-29 |
| AU2001264806A1 (en) | 2001-12-03 |
| PA8517201A1 (es) | 2002-08-26 |
| ECSP024356A (es) | 2003-03-31 |
| WO2001089527A3 (en) | 2003-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4600739A1 (es) | Formulaciones liquidas orales a base de alendronato | |
| ES2194732T3 (es) | Composiciones farmaceuticas orales de liberacion controlada de mesalazina. | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| ES2193726T3 (es) | Formulaciones de aerosol medicinales. | |
| AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| NO20011471D0 (no) | Nye orale vedvarende frigivelsesformuleringer | |
| BR9611523A (pt) | Meios de administração para drogas analgésicas, antiinflamatórias e antipiréticas contendo óxido nitroso e composições farmacêuticas contendo tais meios e drogas. | |
| ES2197792B1 (es) | Formulaciones farmaceuticas que contienen morfina intranasal. | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| CO5170497A1 (es) | Formulaciones liquidas estables de toxina botulinica | |
| AR092919A2 (es) | Composicion farmaceutica liquida | |
| BR9912694A (pt) | Composto para preparar medicamento de administração pulmonar | |
| PE88699A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina | |
| ES2193515T3 (es) | Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo. | |
| ES2110212T3 (es) | Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion. | |
| BR9913135A (pt) | Formulação oral | |
| PE3096A1 (es) | Formulacion conteniendo selenio | |
| PE20020055A1 (es) | Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal | |
| GT199800196A (es) | Combinaciones de estatina-eter carboxialquilico. | |
| AR031649A1 (es) | Composicion farmaceutica de dronedarona para administracion parenteral | |
| PE20030545A1 (es) | Formulaciones de jarabe de ribavirina | |
| ES2142430T3 (es) | Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral. | |
| RS50246B (sr) | Tableta za sisanje, koja sadrži ambroksol | |
| CO5550418A2 (es) | Formulaciones antihistaminicas para formas de dosificacion de capsula blanda | |
| UY27373A1 (es) | Formulaciones de interferón beta-humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |